Nathan Connell: Advancing Prophylaxis for von Willebrand Disease with HMB-002
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn about a recent article by Mattias Häger et al, published in Blood Advances:
”Advancing Prophylaxis for von Willebrand Disease: Introducing HMB-002
Excited to learn more about a significant development in the treatment landscape for von Willebrand Disease (VWD), recently published in Blood Advances.
VWD is the most common inherited bleeding disorder, yet current prophylactic options remain burdensome, often requiring frequent intravenous infusions due to the short half-life of available therapies. Mattias Häger et al. introduce HMB-002, a first-in-class, human Fc-silenced monovalent IgG4 antibody designed to transform VWD management through subcutaneous prophylaxis.
How it works: Unlike traditional replacement therapies, HMB-002 targets the endogenous system. It binds with sub-nanomolar affinity to the C-terminal cysteine-knot (CK) domain of von Willebrand Factor (VWF). Because this domain is spatially distant from VWF’s hemostatic regions, the antibody extends the protein’s half-life without interfering with its vital functions.
Key Findings:
- Significant Elevation: In non-human primates, HMB-002 achieved a sustained ~2-fold elevation of endogenous VWF and Factor VIII (FVIII) levels.
- Functional Preservation: In vitro and ex vivo studies confirmed that HMB-002-bound VWF retains its ability to bind platelets (GPIbα), collagen, and FVIII, and remains susceptible to regulation by ADAMTS13.
- Improved Hemostasis: In a type 1 VWD mouse model, a surrogate antibody recapitulated these results, leading to improved hemostatic control.
- Subcutaneous Convenience: The study demonstrates the potential for a long-acting, subcutaneous treatment that could significantly reduce the treatment burden for patients.
This ‘passive engagement’ strategy represents a sophisticated shift in how we approach protein deficiencies—moving from replacement to half-life extension of the patient’s own hemostatic proteins.
Congratulations to Mattias Häger, Catherine Rea, Benny Sorensen, and the whole team at Hemab Therapeutics on this impactful research!”
Title: HMB-002: A Monovalent Antibody that Elevates Circulating VWF and FVIII Levels for Treatment of Von Willebrand Disease
Authors: Mattias Häger, Minka Zivkovic, Prafull S Gandhi, Caroline Rasmussen, Cécile Bonvoisin, Rane A Harrison, Emil Poulsen, Dana Huskens, Mark Roest, Fortunato Ferrara, Anais Naretto, Lionel Renaud, Ole H Olsen, Nicolas O Eskesen, Lars Holten-Andersen, Ruthvik Malladi, Catherine J Rea, Benny Sørensen, Rolf T Urbanus, Henrik Ostergaard
Read the Full Article on Blood Advances
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy